Oppenheimer & Co. Inc. Acquires New Position in Grail, Inc. (NASDAQ:GRAL)

Oppenheimer & Co. Inc. acquired a new position in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,669 shares of the company's stock, valued at approximately $190,000.

A number of other large investors have also recently made changes to their positions in the business. Bank of New York Mellon Corp bought a new position in Grail during the 4th quarter valued at $6,262,000. TCW Group Inc. purchased a new stake in shares of Grail in the fourth quarter valued at about $5,095,000. abrdn plc bought a new position in shares of Grail during the fourth quarter valued at about $3,768,000. Douglas Lane & Associates LLC purchased a new position in Grail during the fourth quarter worth about $3,034,000. Finally, Slow Capital Inc. bought a new stake in Grail in the 4th quarter worth about $2,379,000.

Insider Buying and Selling at Grail

In related news, CEO Robert P. Ragusa sold 7,625 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.21, for a total value of $237,976.25. Following the completion of the transaction, the chief executive officer now directly owns 828,662 shares of the company's stock, valued at approximately $25,862,541.02. This trade represents a 0.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Aaron Freidin sold 1,816 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $31.20, for a total transaction of $56,659.20. Following the sale, the chief financial officer now directly owns 335,170 shares in the company, valued at $10,457,304. The trade was a 0.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,550 shares of company stock worth $360,436 over the last ninety days.

Remove Ads

Grail Stock Performance

NASDAQ GRAL traded down $3.90 during trading hours on Thursday, reaching $26.95. 1,376,685 shares of the company were exchanged, compared to its average volume of 1,226,842. Grail, Inc. has a 1 year low of $12.33 and a 1 year high of $63.99. The business's 50 day simple moving average is $31.42 and its 200-day simple moving average is $21.15.

Grail (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.41) by $2.55. The company had revenue of $38.25 million for the quarter, compared to analysts' expectations of $35.33 million. On average, research analysts predict that Grail, Inc. will post -15.15 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Morgan Stanley assumed coverage on shares of Grail in a research report on Wednesday, November 27th. They set an "equal weight" rating and a $16.00 target price on the stock. Wolfe Research assumed coverage on Grail in a report on Friday, November 15th. They set a "peer perform" rating on the stock.

Grail Profile

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.